Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.

05/26/2026, 1:00 PM • GlobeNewswire

Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story

Karen Krasney, EVP and General Counsel of Capricor Therapeutics, exercised and sold 25,000 stock options for approximately $793,000 on May 1, 2026, reducing her direct equity position by 45%. The sale was executed under a pre-scheduled 10b5-1 trading plan established in December 2025, indicating a diversification move rather than a loss of confidence. Krasney retains 30,547 common shares and 56,261 unexercised options, maintaining material exposure to the company.

05/10/2026, 7:01 AM • The Motley Fool

Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say

Capricor Therapeutics announced positive Phase 3 HOPE-3 trial results for its cell therapy candidate deramiocel, causing its stock to surge dramatically. Martin Shkreli, who had previously predicted the trial's failure, criticized the data and claimed the company changed its primary endpoint.

12/03/2025, 2:21 PM • Benzinga

Why Capricor Therapeutics Stock Is Surging Today

Capricor Therapeutics met with the FDA to discuss regulatory approval for Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy. The FDA provided clarity on the approval process and showed flexibility in reviewing trial data, causing the stock to surge.

09/25/2025, 11:16 AM • Benzinga

Shareholders of Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights – CAPR

Capricor Therapeutics received a Complete Response Letter from the FDA denying its Biologics License Application for deramiocel, causing a significant stock price drop and triggering a potential securities class action lawsuit.

09/15/2025, 3:58 PM • GlobeNewswire

CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against Capricor Therapeutics alleging false and misleading statements about the safety and efficacy of its Phase 2 HOPE-2 trial for deramiocel, with potential regulatory approval challenges.

09/14/2025, 4:00 PM • GlobeNewswire

CAPR IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in Securities Class Action – CAPR

Rosen Law Firm is pursuing a securities class action lawsuit against Therapeutics for allegedly providing misleading statements about its cell therapy drug deramiocel and its Phase 2 trial data, potentially causing investor damages.

09/14/2025, 9:44 AM • GlobeNewswire

CAPRICOR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Capricor Therapeutics, Inc. of the September 15th Deadline for the Class Action Lawsuit

Bragar Eagel & Squire filed a class action lawsuit against Capricor Therapeutics regarding misleading statements about its cell therapy drug deramiocel. The FDA denied the Biologics License Application, causing the stock price to drop significantly.

09/14/2025, 9:27 AM • GlobeNewswire

CAPR DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 15 Deadline in Securities Class Action – CAPR

Rosen Law Firm alerts Capricor Therapeutics investors about a September 15, 2025 deadline for a securities class action lawsuit related to allegedly misleading statements about a cell therapy drug's safety and efficacy data.

09/11/2025, 4:56 PM • GlobeNewswire

CAPR DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in Securities Class Action – CAPR

Rosen Law Firm alerts Capricor Therapeutics investors about a securities class action lawsuit regarding potentially misleading statements about deramiocel's safety and efficacy data during the period of October 9, 2024 to July 10, 2025.

09/09/2025, 7:57 PM • GlobeNewswire

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

Capricor Therapeutics faces a class action lawsuit alleging false statements about its drug candidate's FDA approval progress, with shareholders encouraged to join a potential recovery effort.

09/08/2025, 1:35 PM • Benzinga

CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. and Encourages Investors to Contact the Firm

A class action lawsuit has been filed against Capricor Therapeutics regarding allegedly misleading statements about its cell therapy drug deramiocel, after the FDA denied its Biologics License Application and the stock price dropped significantly.

09/07/2025, 10:50 AM • GlobeNewswire

Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR

Faruqi & Faruqi is investigating potential claims against Capricor Therapeutics after the FDA denied its Biologics License Application for deramiocel, causing the stock price to drop significantly.

09/07/2025, 8:55 AM • GlobeNewswire

CAPR FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 15 Deadline in Securities Class Action – CAPR

Rosen Law Firm is pursuing a securities class action lawsuit against Therapeutics for allegedly providing misleading information about its cell therapy drug deramiocel during the period of October 9, 2024 to July 10, 2025.

09/05/2025, 7:30 PM • GlobeNewswire

Capricor Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 15, 2025 Deadline to file Lead Plaintiff Motion.

Capricor Therapeutics faces a class action lawsuit alleging misleading statements about its DMD treatment deramiocel, after receiving a Complete Response Letter from the FDA denying its Biologics License Application.

09/05/2025, 5:44 PM • GlobeNewswire